Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14327593 | 0.87 | JAK2 (0.52) | JAK2CYP3A4CCNT1CCNA2CDK2 | |
| SCHEMBL14712339 | 0.86 | JAK2 (0.49) | JAK2CYP1A2CYP3A4CYP2C19CCNT1 | |
| SCHEMBL21014989 | 0.86 | CYP3A4 (0.49) | JAK2CYP1A2CYP3A4CYP2C19CCNT1 | |
| SCHEMBL14327614 | 0.83 | CLK4 (0.46) | JAK2CYP1A2CYP3A4CYP2C19CDK2 | |
| SCHEMBL16626025 | 0.82 | JAK2 (0.45) | JAK2CDK9JAK3 | |
| SCHEMBL10067608 | 0.82 | JAK2 (0.55) | JAK2CYP3A4CCNT1CCNA2CDK2 | |
| SCHEMBL8941812 | 0.81 | CLK4 (0.53) | JAK2CYP1A2CYP3A4CYP2C19CCNT1 | |
| SCHEMBL10304241 | 0.80 | CDC7 (0.59) | JAK2CDK2CDK9JAK3 | |
| SCHEMBL8942639 | 0.80 | JAK2 (0.56) | JAK2CYP3A4CCNT1CCNA2CDK2 | |
| SCHEMBL8942851 | 0.79 | JAK2 (0.65) | JAK2CCNT1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973911-B1 | AZAINDOLES USEFUL FOR THE TREATMENT OF (INTER ALIA) PROLIFERATIVE, CARDIAC, NEURODEGENERATIVE, AUTOIMMUNE OR INFLAMMATORY DISORDERS | VERTEX PHARMA (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| WO-2007084557-A2 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-26 | — | — | WO | disclosed |